Markus J. Schwarz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Markus J. Schwarz has a total of 26 co-authors. Here are the top co-authors by number of shared publications:
Manfred Ackenheil
University of Munich
6 shared publicationsMichael Riedel
Psychiatric Hospital, Ludwig-Maximilian University Munich, Nussbaumstr 7, 80336 Munich, Germany
3 shared publicationsN. Müller
3 shared publicationsNorbert Müller
Psychiatric Hospital, Ludwig-Maximilian University Munich, Nussbaumstr. 7, 80336 Munich, Germany
3 shared publicationsAlexander Neumeister
National Institute of Mental Health
1 shared publicationBrigitta Bondy
1 shared publication
Latest Publications
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
S03-03 - Antiinflammatory treatment approaches in major depression
- 31 December 2010
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 25 (S1)
S03-03 - Antiinflammatory treatment approaches in major depression
- 1 January 2009
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 24 (S1)
The Therapeutic Potential of Non Steroidal Anti-inflammatory Drugs in the Treatment of Depression and Schizophrenia
- 1 January 2009
- Published by Cambridge University Press (CUP) in European Psychiatry
- Vol. 24 (S1)
The Therapeutic Potential of Non Steroidal Anti-inflammatory Drugs in the Treatment of Depression and Schizophrenia
- 1 January 2003
- Published by Springer Nature
- Vol. 527, 265-275
Experimental Evaluation of an Altered Tryptophan Metabolism in Fibromyalgia
Fibromyalgia (FM) is a prevalent syndrome with chronic pain and a hypothesised underlying disturbance of the tryptophan (TRP) metabolism. We performed a tryptophan depletion (TD) test in 17 FM patients and 17 controls. TRP, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), and Interleukin-6 (IL-6) were measured. Additionally pain perception was monitored in the FM patients. FM patients and controls exhibited a decrease of TRP and KYN during TD. 5-HIAA levels also decreased in all controls and in 11 FM patients, but showed a marked increase in 6 FM patients. IL-6 significantly increased during TD in the patients, but not in the controls. Pain perception was not affected in the FM patients. These data demonstrate an altered TRP metabolism in a subgroup of FM patients, where the TD seems to activate 5-HT metabolism and IL-6 production. Our findings may have diagnostic as well as therapeutic implications in the field of fibromyalgia.
- 1 January 2003
- Published by Springer Nature
- Vol. 527, 265-275
Experimental Evaluation of an Altered Tryptophan Metabolism in Fibromyalgia
Fibromyalgia (FM) is a prevalent syndrome with chronic pain and a hypothesised underlying disturbance of the tryptophan (TRP) metabolism. We performed a tryptophan depletion (TD) test in 17 FM patients and 17 controls. TRP, 5-hydroxyindoleacetic acid (5-HIAA), kynurenine (KYN), and Interleukin-6 (IL-6) were measured. Additionally pain perception was monitored in the FM patients. FM patients and controls exhibited a decrease of TRP and KYN during TD. 5-HIAA levels also decreased in all controls and in 11 FM patients, but showed a marked increase in 6 FM patients. IL-6 significantly increased during TD in the patients, but not in the controls. Pain perception was not affected in the FM patients. These data demonstrate an altered TRP metabolism in a subgroup of FM patients, where the TD seems to activate 5-HT metabolism and IL-6 production. Our findings may have diagnostic as well as therapeutic implications in the field of fibromyalgia.
- 1 October 2002
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 252 (5) , 232-234
No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia
Several linkage analyses in schizophrenia research point to a locus on chromosome 6p22, where the gene coding for tumor necrosis factor-α (TNF-α) is located. A marked influence of antipsychotic medication on TNF-α has been described. As the involvement of an immune process in the pathophysiology of schizophrenia has been discussed, a functional TNF-α polymorphism appears to be a candidate in genetic schizophrenia research. The G308A polymorphism of the TNF-α gene was described to be associated with increased TNF-α production. Boin and colleagues have already described a significant association between the polymorphic allele and schizophrenia, investigating 84 schizophrenic patients (21 % polymorphic allele) and 138 healthy volunteers (11 % polymorphic allele), recruited in Northern Italy. We carried out a replication study including 157 schizophrenic patients and 186 healthy persons, who were recruited in Southern Germany. Psychopathology was additionally monitored by PANSS. We were not able to replicate the findings of Boin et al., as we did not find any difference in allele frequency or genotype distribution between our schizophrenic patients (13.7 % polymorphic allele) and healthy controls (16.9 % polymorphic allele). Moreover, we did not find any association between genotype and psychopathology, as measured by PANSS. The different results between these two studies may be due to ethnic differences.
- 1 October 2002
- Published by Springer Nature in European Archives of Psychiatry and Clinical Neuroscience
- Vol. 252 (5) , 232-234
No association between the G308A polymorphism of the tumor necrosis factor-alpha gene and schizophrenia
Several linkage analyses in schizophrenia research point to a locus on chromosome 6p22, where the gene coding for tumor necrosis factor-α (TNF-α) is located. A marked influence of antipsychotic medication on TNF-α has been described. As the involvement of an immune process in the pathophysiology of schizophrenia has been discussed, a functional TNF-α polymorphism appears to be a candidate in genetic schizophrenia research. The G308A polymorphism of the TNF-α gene was described to be associated with increased TNF-α production. Boin and colleagues have already described a significant association between the polymorphic allele and schizophrenia, investigating 84 schizophrenic patients (21 % polymorphic allele) and 138 healthy volunteers (11 % polymorphic allele), recruited in Northern Italy. We carried out a replication study including 157 schizophrenic patients and 186 healthy persons, who were recruited in Southern Germany. Psychopathology was additionally monitored by PANSS. We were not able to replicate the findings of Boin et al., as we did not find any difference in allele frequency or genotype distribution between our schizophrenic patients (13.7 % polymorphic allele) and healthy controls (16.9 % polymorphic allele). Moreover, we did not find any association between genotype and psychopathology, as measured by PANSS. The different results between these two studies may be due to ethnic differences.
- 1 April 2001
- Published by Elsevier in Medical Hypotheses
- Vol. 56 (4) , 483-486
The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms
- 1 April 2001
- Published by Elsevier in Medical Hypotheses
- Vol. 56 (4) , 483-486
The Th2-hypothesis of schizophrenia: a strategy to identify a subgroup of schizophrenia caused by immune mechanisms
- 1 July 1999
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 156 (7) , 1103-1104
Antibodies to Heat Shock Proteins in Schizophrenic Patients: Implications for the Mechanism of the Disease
OBJECTIVE: The involvement of heat shock proteins has been determined in the pathophysiology of several disorders of the central nervous system, including multiple sclerosis. To elucidate their role in schizophrenia, the authors investigated antibody titers to heat shock proteins in unmedicated and medicated patients with schizophrenia. METHOD: Using the enzyme-linked immunosorbent assay technique, the authors measured titers of antibodies to 60 kilodaltons (kD) heat shock proteins (HSP60) and 70 kD heat shock proteins (HSP70) in 30 patients with schizophrenia before and during neuroleptic treatment and compared the titers with those of 31 healthy individuals. RESULTS: Ten (33%) of 30 patients with schizophrenia but only one (3%) of 31 healthy individuals showed immunoreactivity to HSP60 or HSP70. The authors found especially high anti-HSP70 titers in never-medicated patients. High anti-HSP60 titers were mainly found in patients who were being treated with neuroleptics. CONCLUSIONS: Since heat shock proteins are involved in diverse neuroprotective mechanisms, antibodies against heat shock proteins may inhibit neuroprotection. The authors discuss the implications of these findings for schizophrenia.
- 1 July 1999
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 156 (7) , 1103-1104
Antibodies to Heat Shock Proteins in Schizophrenic Patients: Implications for the Mechanism of the Disease
OBJECTIVE: The involvement of heat shock proteins has been determined in the pathophysiology of several disorders of the central nervous system, including multiple sclerosis. To elucidate their role in schizophrenia, the authors investigated antibody titers to heat shock proteins in unmedicated and medicated patients with schizophrenia. METHOD: Using the enzyme-linked immunosorbent assay technique, the authors measured titers of antibodies to 60 kilodaltons (kD) heat shock proteins (HSP60) and 70 kD heat shock proteins (HSP70) in 30 patients with schizophrenia before and during neuroleptic treatment and compared the titers with those of 31 healthy individuals. RESULTS: Ten (33%) of 30 patients with schizophrenia but only one (3%) of 31 healthy individuals showed immunoreactivity to HSP60 or HSP70. The authors found especially high anti-HSP70 titers in never-medicated patients. High anti-HSP60 titers were mainly found in patients who were being treated with neuroleptics. CONCLUSIONS: Since heat shock proteins are involved in diverse neuroprotective mechanisms, antibodies against heat shock proteins may inhibit neuroprotection. The authors discuss the implications of these findings for schizophrenia.
- 1 January 1999
- Published by Elsevier in Neuroscience Letters
- Vol. 259 (3) , 196-198
Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients
- 1 January 1999
- Published by Elsevier in Neuroscience Letters
- Vol. 259 (3) , 196-198
Relationship of substance P, 5-hydroxyindole acetic acid and tryptophan in serum of fibromyalgia patients
- 14 September 1998
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 5 (5) , 270-276
Melanoma-Associated Adhesion Molecule MUC18/MCAM (CD146) and Transcriptional Regulator Mader in Normal Human CNS
The proteins MUC18 and Mader have been identified as markers of tumor progression in melanoma cells. MUC18, also known as MCAM (melanoma cell adhesion molecule) and as CD146 (endothelial antigen), is a cell adhesion molecule belonging to the immunoglobulin superfamily. Mader is a transcriptional regulator shown to negatively regulate EGR-1. As it is known that neoplastic cells of neuroectodermal origin frequently express neuron-specific molecules, we studied whether these melanoma-associated antigens are found in normal CNS tissue. We investigated the expression of MUC18/MCAM and Mader in adult human post mortem CNS tissue by immunohistochemistry, immunoblot and two-dimensional gel electrophoresis. Our results show that Mader is preferentially expressed on neurons and glial cells and that the adhesion protein MUC18/MCAM is mainly expressed on vasculature within the CNS. These observations may have important implications for further studies investigating their possible roles in cell adhesion and proliferation control within the CNS.
- 14 September 1998
- Published by S. Karger AG in Neuroimmunomodulation
- Vol. 5 (5) , 270-276
Melanoma-Associated Adhesion Molecule MUC18/MCAM (CD146) and Transcriptional Regulator Mader in Normal Human CNS
The proteins MUC18 and Mader have been identified as markers of tumor progression in melanoma cells. MUC18, also known as MCAM (melanoma cell adhesion molecule) and as CD146 (endothelial antigen), is a cell adhesion molecule belonging to the immunoglobulin superfamily. Mader is a transcriptional regulator shown to negatively regulate EGR-1. As it is known that neoplastic cells of neuroectodermal origin frequently express neuron-specific molecules, we studied whether these melanoma-associated antigens are found in normal CNS tissue. We investigated the expression of MUC18/MCAM and Mader in adult human post mortem CNS tissue by immunohistochemistry, immunoblot and two-dimensional gel electrophoresis. Our results show that Mader is preferentially expressed on neurons and glial cells and that the adhesion protein MUC18/MCAM is mainly expressed on vasculature within the CNS. These observations may have important implications for further studies investigating their possible roles in cell adhesion and proliferation control within the CNS.
- 1 September 1998
- Published by Elsevier in Neuroscience Letters
- Vol. 253 (3) , 201-203
Blood–cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia
- 1 September 1998
- Published by Elsevier in Neuroscience Letters
- Vol. 253 (3) , 201-203
Blood–cerebrospinal fluid barrier impairment as indicator for an immune process in schizophrenia